CN106038686A - Anti-influenza-virus buccal tablet and preparation method thereof - Google Patents
Anti-influenza-virus buccal tablet and preparation method thereof Download PDFInfo
- Publication number
- CN106038686A CN106038686A CN201610576535.2A CN201610576535A CN106038686A CN 106038686 A CN106038686 A CN 106038686A CN 201610576535 A CN201610576535 A CN 201610576535A CN 106038686 A CN106038686 A CN 106038686A
- Authority
- CN
- China
- Prior art keywords
- micropowder
- buccal tablet
- influenza virus
- resisiting influenza
- herba menthae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an anti-influenza-virus buccal tablet and a preparation method thereof. The anti-influenza-virus buccal tablet comprises the following components in parts by weight: 1-7 parts of dendranthema indicum var aromaticum micropowder, 0.1-2 parts of mint micropowder and 1-9 parts of buccal tablet auxiliary materials. The dendranthema indicum var aromaticum micropowder and the mint micropowder in the anti-influenza-virus buccal tablet are combined, and can achieve synergism in administration, so that the anti-influenza-virus buccal tablet has obvious anti-influenza-virus effect. In addition, the anti-influenza-virus buccal tablet prepared by the preparation method is stable in efficacy, safe, non-toxic, controllable in quality, low in cost and good in industrialization feasibility.
Description
Technical field
The invention belongs to traditional Chinese medicine preparation technical field, be specifically related to a kind of resisiting influenza virus buccal tablet and preparation side thereof
Method.
Background technology
Influenza virus such as H1N1 circulation way: the propagation of influenza virus is mainly air borne, and secondary is that contact passes
Broadcast.Air borne refers to that the people infected by influenza virus such as H1N1 will be with influenza virus such as H1N1 when cough or sneeze
Fine saliva (particle diameter be less than 10 microns) be discharged in air, this slight band poison aerosol-type granule is the most floating,
Will be infected if having sucked this microgranule.
Currently the medicine of infected by influenza is Western medicine mostly, although Western medicine has instant effect feature, but easily produces
Drug resistance.Currently also there is employing treatment by Chinese herbs influenza infection, but existing Chinese medicine exists compatibility complexity, high the asking of cost
Topic.
It addition, by infected by influenza intrusion feature and the research of mode, learn that influenza virus such as H1N1 enters nose or pharynx
Rear rapidly in the soft palate mucosa of oral cavity upper part, schizogamy in the goblet cell of epithelium, then starch with the top of goblet cell and divide
The form of secreting is discharged at oral cavity or nasopharynx, is excreted when cough or sneeze.Therefore, oral instant membrane or buccal tablet are used
It is administered ratio advantageous.
Currently there is the 2nd kind recorded " antivirus oral liquid " this one-tenth antiviral of prescription of standard of being become a full member by Ministry of Public Health new drug
Buccal tablet, but this prescription contains Radix Isatidis, Gypsum Fibrosum, Lu Gen, Radix Rehmanniae, Radix Curcumae, the Rhizoma Anemarrhenae, Shi Yingpu, wide flower bud perfume, Fructus Forsythiae nine taste
Medical material.For anemopyretic cold, epidemic febrile disease heating and upper respiratory tract infection, the virus infectious disease such as influenza, parotitis.But its prescription
Complicated component, cost is high, and specific aim is not strong, and drug effect is to be improved.
Summary of the invention
It is an object of the invention to overcome the above-mentioned deficiency of prior art, it is provided that a kind of resisiting influenza virus buccal tablet and preparation thereof
Method, to solve existing flu buccal tablet complicated component, cost is high, the technical problem that drug effect is to be improved.
In order to realize foregoing invention purpose, the embodiment of the present invention is on the one hand, it is provided that a kind of resisiting influenza virus buccal tablet.Described
Resisiting influenza virus buccal tablet comprises the component of following weight portion:
Dendranthema indicum micropowder 1-7 part
Herba Menthae micropowder 0.1-2 part
Buccal tablet adjuvant 1-9 part.
The embodiment of the present invention is on the other hand, it is provided that the preparation method of a kind of resisiting influenza virus buccal tablet.Described preparation method
Comprise the steps:
Each component raw material is weighed respectively according to component contained by resisiting influenza virus buccal tablet of the present invention；
The each component raw material weighed is carried out mixing treatment, tabletting.
Compared with prior art, resisiting influenza virus buccal tablet of the present invention is with the Dendranthema indicum of effective dose as functional component, by it
After carrying out compatibility with Herba Menthae micropowder, both can play the potentiation of administration, so that resisiting influenza virus buccal tablet of the present invention
There is obvious resisiting influenza virus effect, as H1N1 being had obvious antivirus action, and compatibility of medicines in a prescription function group
Divide kind relatively fewer, on the premise of there is obvious resisiting influenza virus effect, effectively reduce its production cost.
Resisiting influenza virus process for preparing buccal lozenge of the present invention is direct after each function ingredients and buccal tablet adjuvant carry out mixing treatment
Tabletting so that the resisiting influenza virus buccal tablet of preparation not only has an obvious resisiting influenza virus effect, and efficacy stability, safe nothing
Poison, quality controllable, low cost, commercial viability is good.
Detailed description of the invention
In order to make the purpose of the present invention, technical scheme and advantage clearer, below in conjunction with embodiment, to the present invention
It is further elaborated.Should be appreciated that specific embodiment described herein, only in order to explain the present invention, is not used to
Limit the present invention.
The weight of each component that the embodiment of the present invention is noted in the disclosure not only may refer to specifically containing of each component
Amount, it is also possible to represent the proportionate relationship of weight between each component, therefore, as long as each according to embodiment of the present invention description compositions
The content of component scales up or reduces all within embodiment of the present invention description scope of disclosure.Specifically, the present invention
Weight portion described in embodiment description can be unit of weight known to the field of medicaments such as μ g, mg, g, kg, it is of course possible to see
Work is percentage by weight.
On the one hand, a kind of resisiting influenza virus buccal tablet is embodiments provided.In one embodiment, described anti-current is susceptible
Poison buccal tablet comprises the component of following weight portion:
Dendranthema indicum micropowder 1-7 part
Herba Menthae micropowder 0.1-2 part
Buccal tablet adjuvant 1-9 part.
Wherein, described Dendranthema indicum was found in nineteen eighty-two, was then accredited as new varieties of feverfew, this kind of Flos Chrysanthemi
By Herba Dendranthematis indici mutation, it not only has the pharmacological action of Herba Dendranthematis indici, also has the characteristic of its uniqueness, as flower, leaf, stem, root have pole entirely
Strong fragrance.It has been investigated that, the former medical instrument of Dendranthema indicum has antivirus action, after it carries out compatibility with Herba Menthae micropowder, both
The potentiation of administration can be played, also can improve the mouthfeel of buccal tablet simultaneously, so that embodiment of the present invention resisiting influenza virus
Buccal tablet has obvious antivirus action, to as described in influenza virus specifically such as H1N1, there is obvious antivirus action,
Also there is refrigerant mouthfeel.
In one embodiment, described Dendranthema indicum micropowder is that Dendranthema indicum is dried stem and/or leaf micropowder, or is Dendranthema indicum
Extract micropowder.
When Dendranthema indicum micropowder be Dendranthema indicum be dried stem and/or leaf micropowder time, directly Dendranthema indicum can be dried stem
And/or leaf raw material carries out pulverization process.In one embodiment, described Dendranthema indicum micropowder is to smash acquisition as follows:
Dendranthema indicum is dried stem and/or leaf raw material uses collision type air-flow disintegrating machine smashing to process, and at described smashing
Reason arranges process conditions and is:
Working media: compressed air
Air demand: 6M3/m:n
Operating pressure: 0.8-1.0Mpa
Feed pressure: 0.2-0.4Mpa
Size :≤7 microns
Charging particle diameter: >=80 mesh.
By the control to disintegrating process condition so that after pulverizing, Dendranthema indicum is dried stem and/or leaf grain size of micropowder≤7 are micro-
Rice, thus improve the absorbent properties of medicine.
When Dendranthema indicum micropowder is Dendranthema indicum extract micropowder, in one embodiment, described Dendranthema indicum extract
Obtain under the conditions of following extraction concentrates:
Using Dendranthema indicum to be dried stem and/or leaf is raw material, use flooding to process, concentrate drying processes；Wherein, described
The condition that extraction processes is: Extracting temperature 50 DEG C-60 DEG C, extraction time 24-48h, the volume ratio (9-20) of Extraction solvent feed liquid:
1；Wherein, the condition of described concentration is: thickening temperature 50 DEG C-80 DEG C, concentrates pressure and bears 0.08MPa for negative 0.06-.
By the control of extracting factor raw-material to Dendranthema indicum, to realize Dendranthema indicum extract drug effect is become
Divide and the control of content, face with the resisiting influenza virus such as anti-H 1 N 1 giving embodiment of the present invention resisiting influenza virus buccal tablet good
Bed effect.The Dendranthema indicum extract obtained can be lyophilized or be condensed into paste.
After this Dendranthema indicum extract such as lyophilizing extract to be extracted, can according to above-mentioned Dendranthema indicum is dried stem and/
Or leaf raw material uses the smashing condition of collision type air-flow disintegrating machine smashing process to pulverize, it would however also be possible to employ other smash mode
Pulverizing, the size controlling of the Dendranthema indicum extract after pulverizing the most at last is at≤7 microns.It is, of course, also possible to directly will carry
Take this Dendranthema indicum extract and be condensed into paste, with other components be fully mixed even after carry out tabletting.
In one embodiment, no matter Dendranthema indicum micropowder is that Dendranthema indicum is dried stem and/or leaf micropowder, or Dendranthema indicum
Extract micropowder, preferably controls the a-lindestrene that Dendranthema indicum micropowder contains mass percent 0.1%-2%.To ensure that the legendary god of farming is fragrant
The drug effect of the resisiting influenza virus of chrysanthemum micropowder is obvious.
On the basis of the various embodiments described above, the weight portion of Dendranthema indicum micropowder can be 1 part.
There is the effect playing penetrating agent in above-mentioned Herba Menthae micropowder, it is possible to functional component Dendranthema indicum micropowder plays synergistic and makees
With, improve the clinical effect of embodiment of the present invention resisiting influenza virus buccal tablet resisiting influenza virus.Simultaneously as the specific taste of menthol
Road, also acts as flavoring agent effect.
In one embodiment, described Herba Menthae micropowder is that Herba Menthae is dried stem and/or leaf micropowder or Herba Menthae extract micropowder.
When Herba Menthae micropowder be Herba Menthae be dried stem and/or leaf micropowder time, directly Herba Menthae can be dried stem and/or leaf raw material enters
Row pulverization process.In one embodiment, described Herba Menthae is dried stem and/or leaf micropowder is to smash acquisition as follows:
Herba Menthae is dried stem and/or leaf raw material uses collision type air-flow disintegrating machine smashing to process, and described smashing processes and sets
Putting process conditions is:
Working media: compressed air
Air demand: 6M3/m:n
Operating pressure: 0.8-1.0Mpa
Feed pressure: 0.2-0.4Mpa
Size :≤7 microns
Charging particle diameter: >=80 mesh.
By the control to disintegrating process condition so that after pulverizing, Herba Menthae is dried stem and/or leaf grain size of micropowder≤7 micron,
Thus improve the absorbent properties of medicine, thus improve the synergistic effect between functional component Dendranthema indicum micropowder.
When Herba Menthae micropowder is Herba Menthae extract micropowder, in one embodiment, described Folium Menthae extract is to extract following
Obtain under the conditions of concentration:
Using Herba Menthae to be dried stem and/or leaf is raw material, use dehydrated alcohol extraction to process, concentrate drying processes；Wherein, institute
The condition stating extraction process is: Extracting temperature 50 DEG C-60 DEG C, extraction time 16-36h, the volume ratio of Extraction solvent feed liquid are (9-
15)∶1；Wherein, the condition of described concentration is: thickening temperature 50 DEG C-80 DEG C, concentrates pressure and bears 0.08MPa for negative 0.06-.
By the control of extracting factor raw-material to Herba Menthae, to realize Folium Menthae extract active ingredient and the control of content,
Thus improve the synergistic effect between functional component Dendranthema indicum micropowder, to give embodiment of the present invention resisiting influenza virus buccal tablet
Good resisiting influenza virus such as anti-H 1 N 1 clinical effect.The Folium Menthae extract obtained can be lyophilized or be condensed into cream
Shape thing.
This Folium Menthae extract to be extracted, can be according to above-mentioned stem and/or the leaf raw material of being dried by Dendranthema indicum as after lyophilized powder
The smashing condition using collision type air-flow disintegrating machine smashing to process is pulverized, it would however also be possible to employ other smashing modes carry out powder
Broken, the size controlling of the Folium Menthae extract after pulverizing the most at last is at≤7 microns.It is, of course, also possible to directly this Herba Menthae of extraction is carried
Take thing and be condensed into paste, with other components be fully mixed even after carry out tabletting.
In one embodiment, no matter Herba Menthae micropowder is that Herba Menthae is dried stem and/or leaf micropowder, or Herba Menthae extract micropowder,
Preferably control the menthone that Herba Menthae micropowder contains mass percent 0.5%-1%.To improve the penetrating agent effect of Herba Menthae micropowder, and
The drug effect of the resisiting influenza virus of the potentiation between enhancing Herba Menthae micropowder and Dendranthema indicum micropowder is obvious.
On the basis of the various embodiments described above, Herba Menthae micropowder weight portion can be 0.5 part.
Above-mentioned buccal tablet adjuvant can be that this area can accept for the medicine preparing tablet.This pharmaceutically acceptable adjuvant is
Refer to any adjuvant being suitable for this specific mode of administration well known by persons skilled in the art.As in a particular embodiment, this medicine
The acceptable adjuvant of thing can include the pharmaceutically acceptable carrier of one or more tablets, solvent, excipient, buffer agent, steady
Determine agent, adjuvant, prodrug and treatment to benefit from relieving constipation or strengthen the other therapeutic agents of above-mentioned resisiting influenza virus buccal tablet activity.Should
When being understood by, above-mentioned each buccal tablet adjuvant should be nontoxic, do not disturb or not damage the above-mentioned anti-current of the embodiment of the present invention susceptible
The function of poison buccal tablet and effect.Such as, in one embodiment, described buccal tablet adjuvant includes in cane sugar powder, mannitol, sorbitol
At least one.
On the basis of the various embodiments described above, buccal tablet adjuvant weight portion can be 1.5 parts.
On the basis of embodiments described above, as one embodiment of the invention, described Dendranthema indicum micropowder
Weight portion is 1 part, the weight portion of Herba Menthae micropowder is 0.5 part, the weight portion of buccal tablet adjuvant is 1.5 parts.By adjusting each component
Content, improves the potentiation between each component, improve resisiting influenza virus buccal tablet functional component absorbed power and function ingredients it
Between synergistic effect, thus improve drug effect and the release medicine of buccal tablet of embodiment of the present invention resisiting influenza virus buccal tablet resisiting influenza virus
Thing speed.
From the above mentioned, embodiment of the present invention resisiting influenza virus buccal tablet carries out compatibility by Dendranthema indicum micropowder and menthol,
Both can play the potentiation of administration, so that embodiment of the present invention resisiting influenza virus buccal tablet has obvious influenza
Virus function, uses safety, simplifies compatibility of medicines in a prescription composition, reduces Financial cost.
On the other hand, on the basis of the invention described above embodiment, the embodiment of the present invention provides anti-current mentioned above susceptible
A kind of preparation method of poison buccal tablet.In one embodiment, embodiment of the present invention resisiting influenza virus process for preparing buccal lozenge includes walking as follows
Rapid:
Step S01: the component contained by embodiment of the present invention resisiting influenza virus buccal tablet as described above weighs respectively respectively
Component raw material；
Step S02: each component raw material step S01 weighed carries out mixing treatment, tabletting；
Wherein, component contained by resisiting influenza virus buccal tablet described in above-mentioned steps S01 and each constituent content as described above, for
Saving length, does not repeats them here.
Mixing treatment in above-mentioned steps S02 can be medical material conventional method method for mixing, it is also possible to the most just at pulverizing
Batch mixing is realized, the most in which way, as long as be capable of both batch mixings uniformly during reason.
Tabletting in this step S02 can be prepared according to conventional buccal tablet medicine.It is axiomatic that treat at tabletting
After reason, also include the subsequent processing steps of tabletting, such as drying and other steps.
Therefore, each function ingredients and buccal tablet adjuvant are carried out batch mixing by embodiment of the present invention resisiting influenza virus process for preparing buccal lozenge
Direct compression after process so that the resisiting influenza virus buccal tablet of preparation not only has an obvious resisiting influenza virus effect, and drug effect
Stable, safety non-toxic, quality controllable, low cost, commercial viability is good.
Below by way of resisiting influenza virus buccal tablet and preparation method thereof specific embodiment, the present invention will be further described.
Embodiment 1
The present embodiment provides a kind of resisiting influenza virus buccal tablet and preparation method thereof.This resisiting influenza virus buccal tablet prescription every contains
There is a following component:
Containing a-lindestrene (0.1%-2%) Dendranthema indicum micropowder: 1g
Containing menthone (0.5%-1%) mentha leave micropowder: 0.5g
Adjuvant: 1.5g
Wherein, adjuvant includes that at least one in cane sugar powder, mannitol, sorbitol, Dendranthema indicum micropowder are fragrant with the legendary god of farming
Chrysanthemum crude drug directly carries out pulverizing by following pulverization conditions and is formed；Mentha leave micropowder be with mentha leave raw material directly by with
Lower pulverization conditions carries out pulverizing and is formed:
Being produced as follows of the super fine of Dendranthema indicum micropowder and mentha leave micropowder:
With JGM-T type Counter-impact flow pulverizer comminuted starting materials, its working index is as follows:
Working media: compressed air
Air demand: 6M3/m:n
Operating pressure: 0.8-1.0Mpa
Feed pressure: 0.2-0.4Mpa
Size: < 7 microns
Charging particle diameter: >=80 mesh
Rewinding form: can closed loop classification.
The preparation method of resisiting influenza virus buccal tablet is as follows:
Prepare respectively according to the manufacture method of above-mentioned the present embodiment 1 Dendranthema indicum micropowder and the super fine of mentha leave micropowder
Dendranthema indicum micropowder and mentha leave micropowder, and proportionally weigh adjuvant, the main ingredient weighed accurately is weighed, then puts stirring
Carrying out system after device mix homogeneously to contain: make 1000 tablets of buccal tablets by 3Kg, counting every weight is 3g, and the every powder 1g Han Dendranthema indicum is thin
Folium Nelumbinis powder 0.5g.Adjuvant is performed by " Chinese Pharmacopoeia " 2015 editions relevant buccal tablet adjuvant standards.
Embodiment 2
The present embodiment provides a kind of resisiting influenza virus buccal tablet and preparation method thereof.This resisiting influenza virus buccal tablet prescription every contains
There is a following component:
Containing a-lindestrene Dendranthema indicum extract micropowder: 4g
Herba Menthae extract micropowder containing menthone: 1g
Adjuvant: 5g.
Wherein, Dendranthema indicum extract micropowder and Herba Menthae extract micropowder are to carry respectively according to extracting method above respectively
Taking, resisiting influenza virus process for preparing buccal lozenge is according to the preparation method of resisiting influenza virus buccal tablet in embodiment 1.
Embodiment 3
The present embodiment provides a kind of resisiting influenza virus buccal tablet and preparation method thereof.This resisiting influenza virus buccal tablet prescription every contains
There is a following component:
Containing a-lindestrene Dendranthema indicum extract micropowder: 7g
Herba Menthae extract micropowder containing menthone: 2g
Adjuvant: 8g.
Wherein, Dendranthema indicum extract micropowder and Herba Menthae extract micropowder are to carry respectively according to extracting method above respectively
Taking, resisiting influenza virus process for preparing buccal lozenge is according to the preparation method of resisiting influenza virus buccal tablet in embodiment 1.
The test of pesticide effectiveness
By embodiment 1-3 provide buccal tablet mill and use physiological saline solution, be diluted to the most respectively 1:50,1:100,1:
The diluent of 150.
Being diluted by H1N1 PBS, kill anti-viral test with the Embryo Gallus domesticus of hatching 10, Embryo Gallus domesticus divides 6 groups, 1 group is that H1N1 is strong
Poison group；2 groups is in H1N1 standard serum and group；3,4,5 groups are respectively tri-groups of medicine 1:50,1:100,1:150；6 groups is PBS
Matched group.Wherein, the resisiting influenza virus buccal tablet suppression H that embodiment 1 provides1N1The test of pesticide effectiveness be described in table 1 below.
Table 1 Dendranthema indicum buccal tablet suppression H1N1 effect observation table
From poison group (1 group) Embryo mortality in 84 hours higher (86%) strong seen from upper table 1, medication group (3,4,5 groups),
Only the 4th group (Drug level is 1:100) dead 1 (mortality rate is 0.6%) in 48 hours, has notable difference, explanation
Medicine restrained effectively viral growth.
Respectively the offer of embodiment 2-3 is resisted according to the test of pesticide effectiveness model of the resisiting influenza virus buccal tablet of embodiment 1 offer
Influenza virus buccal tablet carries out the test of pesticide effectiveness, understands through test data, the drug effect of the resisiting influenza virus buccal tablet that embodiment 2-3 provides
Approximating with embodiment 1 result of the test, Embryo mortality is low in 48 hours for medication group (3,4,5 groups), with the chicken of strong poison group (1 group)
Embryo mortality rate has notable difference, illustrates that the resisiting influenza virus buccal tablet that the embodiment of the present invention provides has obvious resisiting influenza virus
Effect, as having obvious antivirus action to H1N1, restrained effectively viral growth.
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all essences in the present invention
Any amendment, equivalent and the improvement etc. made within god and principle, should be included within the scope of the present invention.
Claims (10)
1. a resisiting influenza virus buccal tablet, it is characterised in that: comprise the component of following weight portion:
Dendranthema indicum micropowder 1-7 part
Herba Menthae micropowder 0.1-2 part
Buccal tablet adjuvant 1-9 part.
Resisiting influenza virus buccal tablet the most according to claim 1, it is characterised in that: described Dendranthema indicum micropowder 1 part, Herba Menthae are micro-
0.5 part of powder, buccal tablet adjuvant 1.5 parts.
Resisiting influenza virus buccal tablet the most according to claim 1 and 2, it is characterised in that: described Dendranthema indicum micropowder is the legendary god of farming
Folium Crossostephii Chinensis is dried stem and/or leaf micropowder, or is Dendranthema indicum extract micropowder.
Resisiting influenza virus buccal tablet the most according to claim 3, it is characterised in that: described Dendranthema indicum extract is as follows
Obtain under the conditions of extracting concentration:
Using Dendranthema indicum to be dried stem and/or leaf is raw material, use flooding to process, concentrate drying processes；Wherein, described extraction
The condition processed is: Extracting temperature 50 DEG C-60 DEG C, extraction time 24-48h, the volume ratio (9-20) of Extraction solvent feed liquid: 1；Its
In, the condition of described concentration is: thickening temperature 50 DEG C-80 DEG C, concentrates pressure and bears 0.08MPa for negative 0.06-.
Resisiting influenza virus buccal tablet the most according to claim 1 and 2, it is characterised in that: described Herba Menthae micropowder is that Herba Menthae is dried
Stem and/or leaf micropowder or Herba Menthae extract micropowder.
Resisiting influenza virus buccal tablet the most according to claim 5, it is characterised in that: described Folium Menthae extract is to extract following
Obtain under the conditions of concentration: use Herba Menthae to be dried stem and/or leaf is raw material, use dehydrated alcohol extraction to process, at concentrate drying
Reason；Wherein, the condition that described extraction processes is: Extracting temperature 50 DEG C-60 DEG C, extraction time 16-36h, Extraction solvent feed liquid
Volume ratio is (9-15): 1；Wherein, the condition of described concentration is: thickening temperature 50 DEG C-80 DEG C, and it is negative for concentrating pressure
0.06-bears 0.08MPa.
7. according to the arbitrary described resisiting influenza virus buccal tablet of claim 1,2,4,6, it is characterised in that: described Dendranthema indicum micropowder
And/or the pulverizing of Herba Menthae micropowder is to smash acquisition as follows:
Dendranthema indicum is dried stem and/or leaf raw material, Dendranthema indicum extract, Herba Menthae is dried stem and/or leaf raw material or Herba Menthae carries
Any one uses collision type air-flow disintegrating machine smashing to process to take thing, and described smashing processes and arranges process conditions and be:
Working media: compressed air
Air demand: 6M3/m:n
Operating pressure: 0.8-1.0Mpa
Feed pressure: 0.2-0.4Mpa
Size :≤7 microns
Charging particle diameter: >=80 mesh.
8. according to the arbitrary described resisiting influenza virus buccal tablet of claim 1,2,4,6, it is characterised in that: described Dendranthema indicum micropowder
A-lindestrene containing mass percent 0.1%-2%；And/or described Herba Menthae micropowder contains mass percent 0.5%-1%
Menthol.
9. according to the arbitrary described resisiting influenza virus buccal tablet of claim 1,2,4,6, it is characterised in that: described buccal tablet adjuvant includes
At least one in cane sugar powder, mannitol, sorbitol.
10. the preparation method of a resisiting influenza virus buccal tablet, it is characterised in that comprise the steps:
Each component raw material is weighed respectively according to component contained by the arbitrary described resisiting influenza virus buccal tablet of claim 1-9；
The each component raw material weighed is carried out mixing treatment, tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610576535.2A CN106038686B (en) | 2016-07-20 | 2016-07-20 | Anti-influenza virus buccal tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610576535.2A CN106038686B (en) | 2016-07-20 | 2016-07-20 | Anti-influenza virus buccal tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106038686A true CN106038686A (en) | 2016-10-26 |
| CN106038686B CN106038686B (en) | 2020-05-22 |
Family
ID=57187442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610576535.2A Active CN106038686B (en) | 2016-07-20 | 2016-07-20 | Anti-influenza virus buccal tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106038686B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106617262A (en) * | 2016-12-14 | 2017-05-10 | 湖北中烟工业有限责任公司 | Tobacco buccal tablet and preparation method thereof |
-
2016
- 2016-07-20 CN CN201610576535.2A patent/CN106038686B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| 何希望等，: "基于功效和毒性的薄荷化学成分研究进展", 《中国药物警戒》 * |
| 史晨希等，: "野菊花水提物体内外抗甲1型流感病毒(H1N1)作用研究", 《中药材》 * |
| 时霄霄: "《邹平中药志》", 31 January 2015 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106617262A (en) * | 2016-12-14 | 2017-05-10 | 湖北中烟工业有限责任公司 | Tobacco buccal tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106038686B (en) | 2020-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100486635C (en) | Pharyngitis treating Chinese medicine | |
| US20230113539A1 (en) | Traditional Chinese medicine for dispersing lung qi and detoxicating | |
| CN104585733B (en) | Cordyceps oral tablet and preparation method thereof | |
| WO2021208335A1 (en) | Traditional chinese medicine composition capable of removing toxins, dispelling dampness, and disinhibiting throat, and application thereof | |
| CN102068480A (en) | Edible and medicinal compound preparation with effects of heatstroke alleviation and detoxification | |
| CN101468089B (en) | Chinese medicinal composition for diffusing lung, relieving exterior syndrome, suppressing cough and reducing phlegm and preparation method thereof | |
| WO2012048526A1 (en) | Chinese medicine product for clearing lungs, relieving asthma, and reducing phlegm | |
| CN107625828A (en) | A kind of health protection tea for auxiliary treatment chronic pharyngitis, preparation method and application | |
| CN106038686A (en) | Anti-influenza-virus buccal tablet and preparation method thereof | |
| CN101088533A (en) | Antiviral Chinese medicine prepn and its prepn process, quality control method and application | |
| CN102600312A (en) | Medicine composition with effect of preventing influenza | |
| CN102641335A (en) | Traditional Chinese medicine composition for treating upper respiratory tract viral infection and preparation method thereof | |
| CN114903956A (en) | Chinese herbal medicine composition for preventing and treating pig diseases and preparation method and application thereof | |
| CN104547174B (en) | Preparation method of the fowl with anti virus herb granule | |
| CN101024060B (en) | Jinsangsanjie preparation preparing method | |
| CN1966051B (en) | Antivirus medicament for resisting virus | |
| CN106389984A (en) | Pharmaceutical composition for treating chronic bronchitis and preparation method thereof | |
| CN106361805A (en) | Traditional Chinese medicine composition with throat clearing effect, and preparation method and preparation thereof | |
| CN111529625A (en) | Traditional Chinese medicine formula for preventing re-workers from infecting new coronary pneumonia and tea bag | |
| CN111265554A (en) | Application of antiviral compound composition in resisting HIV virus, SARS virus and leukemia virus | |
| CN104815217A (en) | Pharmaceutical composition for treating pigeon body psoroptic mange and preparation method of pharmaceutical composition | |
| CN103893240A (en) | Composition for preventing and/or treating respiratory system diseases caused by hazes | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof | |
| CN105267291B (en) | Compound composition for treating or protecting liver injury | |
| CN103705857B (en) | For preventing the Chinese medicine composition of oral cavity radiomucitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 518000 room 702, Pioneer Park, University Town, Taoyuan street, Nanshan District, Shenzhen, Guangdong Applicant after: Shenzhen Shennong special medicine food Development Co Ltd Address before: 518000 room 702, Pioneer Park, University Town, Taoyuan street, Nanshan District, Shenzhen, Guangdong Applicant before: SHENZHEN SHENNONG SPRING PLANT SUBSTANCES DEVELOPMENT CO., LTD. |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 518000 Shenzhen District, Longhua, Guangdong province Longhua Street Qinglong Road 6, Hong Kong Science and Technology Park incubator 3 floor E area Applicant after: Shenzhen Shennong Special Medical Food Co., Ltd. Address before: 518000 Guangdong Shenzhen Nanshan District Taoyuan Street Li Shan Road University Town Pioneer Park 702 room Applicant before: Shenzhen Shennong special medicine food Development Co Ltd |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |